NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...
Shares of Regeneron Pharmaceuticals Inc. slid 3.61% to $665.46 Tuesday, on what proved to be an all-around favorable trading ...
In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...
InsideNoVa (English) on MSN20h
Colgan High School senior named finalist in prestigious science and math competitionA Colgan High School senior was named one of the top 40 finalists in the 2025 Regeneron Science Talent Search, a prestigious ...
The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...
Seven rheumatology researchers have authored a paper questioning the utility of the 2024 National Academies’ broad definition of long COVID.
With many biotechs and pharmas needing to fill impending revenue holes coming later in the decade, M&A is posed to pick up, but not until government and regulatory uncertainty settles down. Dealmaking ...
The AI server maker said adjusted earnings for its fiscal second quarter was 58 cents to 60 cents a share, compared with the FactSet consensus for 61 cents.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback